Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Jefferies Global Healthcare Conference 2025
24 slides from Cytosorbents's conference presentation, Jun 5, 2025
Slide 1: Jefferies Global Healthcare Conference
NASDAQ: CTSO Jefferies Global Healthcare Conference June 5, 2025 1 |
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 3: CytoSorbents at a Glance
CytoSorbents at a Glance • Platform blood purification technology for removing toxins and harmful substances from the blood • High margin “razorblade” disposables that are “plug and play” into existing hospital blood pumps • Two main products leveraging the underlying polymer technology CytoSorb • T
Slide 4: The Power of the Bead
The Power of the Bead Hemocompatible, highly porous polymer bead platform technology that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration • Excellent removal of a broad range of substances from whole blood and plasma • Solid state porous p
Slide 5: Expanding the Dimension of Blood Purification
Expanding the Dimension of Blood Purification CytoSorb removes a broad range of harmful substances that dialysis does not CytoSorb works like the liver Dialysis works like the kidney Large Molecules and Fat soluble substances Small Molecules and Water soluble substances Cytokines Inflammatory mediat
Slide 6: CytoSorb: Our Core Business
CytoSorb Our Core Business 6 |
Slide 7: CytoSorb Targets Massive Inflammation - the Heart of Critical Illness
CytoSorb Targets Massive Inflammation - the Heart of Critical Illness • Acute inflammation is the body’s mechanism to fight injury and infection • However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death CAPILLARY IMMUNE S
Slide 8: CytoSorb Integrated Approach for Critical Care
CytoSorb Integrated Approach for Critical Care Right Break the Cycle Patient of Deadly Inflammation Highest Chance for Reverse Good Instability Clinical Outcome Right Right Timing Dose Restore and Preserve Organ Function Just like antibiotics… Treat early, treat aggressively, & complete the full cou
Slide 9: 2025: Early and Intensive Treatment with More Blood Treated Works Best
2025: Early and Intensive Treatment with More Blood Treated Works Best 9 |
Slide 10: 2025: First Meta-Analysis in Septic Shock
2025: First Meta-Analysis in Septic Shock Septic shock is a dreaded complication of sepsis resulting in a potentially lethal drop in blood pressure with a high expected mortality. CytoSorb can reverse shock and reduce mortality • 2025 Meta-analysis is the first to specifically investigate the use of
Slide 11: The Opportunity of DrugSorb-ATR
The Opportunity of 11 | * The DrugSorb-ATR system is an investigational device that is not yet cleared/approved by FDA, Health Canada, or by any other Global Regulatory Agency and is not commercially available for sale
Slide 12: Large Unmet Need for Blood Thinner Reversal
Large Unmet Need for Blood Thinner Reversal Millions of people worldwide are on Anti-thrombotic blood thinners to reduce risk of heart attack and stroke Brilinta® (ticagrelor) Eliquis® (apixaban) Xarelto® (rivaroxaban) (AstraZeneca) (Pfizer, BMS) (Bayer, Jansenn/J&J) Acute Coronary Syndrome, Atrial
Slide 13: DrugSorb-ATR is an FDA Breakthrough Device
DrugSorb-ATR is an FDA Breakthrough Device • DrugSorb-ATR is an investigational device that uses an equivalent polymer technology to CytoSorb and installs easily into a cardiopulmonary bypass machine * • As whole blood is pumped through the cartridge, it is designed to remove free drug during surger
Slide 14: Brilinta and the Use Case for DrugSorb-ATR
® Brilinta and the Use Case for 5 - 10% will need open heart surgery The ultimate goal of DrugSorb-ATR is to allow patients to get the critical surgery they need without X X XX X delay, while reducing or preventing 14 | bleeding complications
Slide 15: The Pivotal STAR-T RCT
The Pivotal STAR-T RCT In the U.S. & Canadian 140-patient pivotal STAR-T RCT evaluating the safety and efficacy of DrugSorb-ATR to reduce the severity of perioperative bleeding in cardiac surgery patients when used within 2 days of Brilinta (ticagrelor, AstraZeneca) discontinuation, the Principal In
Slide 16: STAR Registry: Real World Evidence
STAR Registry: Real World Evidence • STAR Registry now in 6 countries (GER, UK, BEL, AUT, SWE, CH) with 600+ subjects enrolled in different cardiac surgeries • Ticagrelor removal in 102 CABG patients now published • Ticagrelor removal in an updated cohort of 150 CABG patients presented in Paris at E
Slide 17: Statistically and Clinically Significant Impact on Bleeding
Statistically and Clinically Significant Impact on Bleeding Bleeding Transfusions Revisions 40.0% p<0.001 p<0.001 p=0.02 35.0% Two real-world cohorts of patients 33.0% on ticagrelor undergoing isolated 30.0% on-pump CABG before completing the recommended washout were 25.0% 27.0% compared: ↓68% 20.0%
Slide 18: FDA and Health Canada Regulatory Update
FDA and Health Canada Regulatory Update • FDA De Novo submission and Medical Device License application to Health Canada included STAR-T RCT data and STAR registry real world evidence (RWE) • Interactive review with FDA resolved many issues, however, a denial letter was issued April 25, 2025 • Subse
Slide 19: Large Total Addressable Market
Large Total Addressable Market Future Opportunity $1+ Billion Near-Term Opportunity >$600M >$200M >$150M >$450M >$450M Initial Opportunity >$300M • U.S. & CAN Ticagrelor Removal in CABG • DOAC Removal in CABG • DOAC Removal in Hospital-Wide Applications • Expansion of U.S. & CAN • U.S. & CAN Ticagre
Slide 20: Financial Performance
20 Financial Performance CytoSorbents.
Slide 21: Annual Product Sales
Annual Product Sales CytoSorbents sells through Direct Sales in 9 countries and Distributors in 63+ others Recent Financial Performance $45.0 Annual Product Sales FY2024 1Q25 $39.5M $40.1M $40.0 $6.3 $9.4 $35.0 $35.6M Revenue $35.6M $8.7M $35.6 $33.8 $31.1M* $30.0 $29.4M* Growth % 15% (3%) / 0%** $3
Slide 22: Strengthened Balance Sheet with Goal to Drive Core Business to Near Cash-Flow Breakeven
Strengthened Balance Sheet with Goal to Drive Core Business to Near Cash-Flow Breakeven in 2H 2025 • $7.85 million received from successful Rights Offering in Q1 2025 that unlocked $5.0M in restricted cash on our balance sheet • $13.1 million in cash, cash equivalents and restricted cash at March 31
Slide 23: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition CytoSorb is the basis of our established, international core business in critical care and cardiac surgery with $35M+ in high margin product sales with expectations for growth due to: • Significant market opportunity, targeting major unmet medical needs • “Ri
Slide 24: CytoSorbents Corporation
CytoSorbents Corporation NASDAQ: CTSO Company Contact: Dr. Phillip Chan pchan@cytosorbents.com 908-307-0367 www.cytosorbents.com 24
CytoSorbents — Jefferies Global Healthcare Conference 2025 on 6ix